When a restructuring is planned to cost $2.5 billion, you know it includes a lot of cuts. The fact GSK refused to disclose the number as of yet says enough on its own. At least it will be spread over the next three years, so it won't be an immediate shock. Or so I hope.
There are no replies in this thread yet. Be the first to post a reply below: